In 2023, the number of biotechnology research and experimental development enterprises in France stood at approximately 1.08 thousand. From 2024 to 2028, the forecast predicts a stable growth in the sector, with enterprises expected to slightly increase from 1.09 thousand in 2024 to 1.1 thousand by 2025, maintaining this level through 2028. This represents a negligible year-on-year increase of about 0.92% from 2023 to 2024, remaining constant in subsequent years. Over the five-year period from 2024 to 2028, the compound annual growth rate (CAGR) is expected to be minimal, reflecting steady market conditions.
Future trends to watch for include:
- Technological advancements and increased government investment potentially catalyzing more dynamic growth.
- The evolution of regulations may impact market expansion and operational dynamics.
- Global partnerships and collaborations influencing domestic enterprise growth and innovation.
